Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 12 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 von Hippel-Lindau Disease 2 Pheochromocytoma 1 Paraganglioma 1 Kidney Neoplasms 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Fulvestrant 34 Specimen Handling 31 Letrozole 30 Paclitaxel 23 pembrolizumab 19 Carboplatin 19 ribociclib 18 exemestane 18 Capecitabine 17 Trastuzumab 16 Tamoxifen 16 Magnetic Resonance Spectroscopy 16 palbociclib 15 Anastrozole 15 Biopsy 14 trastuzumab deruxtecan 13 abemaciclib 13 pertuzumab 11 Radiotherapy 11 Cyclophosphamide 9 inavolisib 8 elacestrant 8 olaparib 7 Taxes 7 Standard of Care 7 Radiation 7 Mastectomy, Segmental 7 Goserelin 7 130-nm albumin-bound paclitaxel 7 giredestrant 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × belzutifan × 30 days × Clear all

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡